Recentin

Recentin Uses, Dosage, Side Effects, Food Interaction and all others data.

The novel indole-ether quinazoline Recentin is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Recentin is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors. The preclinical profile of Recentin indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor. Phase I data indicate that Recentin is generally well tolerated, with the most common dose related adverse events being diarrhoea, hoarseness, headache and hypertension.

Recentin
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Recentin
Generic	Cediranib
Cediranib Other Names	Cediranib
Type
Formula	C₂₅H₂₇FN₄O₃
Weight	Average: 450.5053 Monoisotopic: 450.206718955
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

How Recentin works

Recentin inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK). By forming a blockade at the VEGF receptors, Recentin limits the growth of new blood vessels, which are essential to supporting tumor growth. Thus, lacking sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth and potentially improving the efficacy of other treatments. Preclinical evidence indicated that the drug had a high affinity at these sites, and was well tolerated and efficacious in animal studies.